If you're eager to send 2011 off into the history books, you're not alone. It has been a tough year for many companies out there, sending gobs of stocks down near their 52-week lows. Here are a few that have disappointed investors this year:
52-Week Price Range
|Cell Therapeutics ||(52.2%)||$1.06||$0.95-$3.30|
|Keryx Biopharmaceuticals ||(47.3%)||$2.41||$2.27-$5.55|
Let's take a closer look at what's been ailing these outfits.
Cell Therapeutics has been turning investors off by boosting its share count, earlier this month announcing its second stock offering since June. When companies issue new shares of stock, they dilute the ownership stake of existing shares. Presumably, the company is accumulating cash to help promote its drug pixantrone, but as my colleague David Williamson has pointed out, it might have waited for FDA approval first. An approval would likely propel shares upward, making a stock offering more effective. Approval is not a sure thing, though -- the FDA already dissed the drug once.
Keryx Biopharmaceuticals looks promising in some respects, such as its pipeline. It's developing a colorectal cancer drug, perifosine, with Aeterna Zentaris
You might think that Dendreon would be in good shape, with its prostate cancer drug Provenge approved and in production. But alas, it has had a tough year, too. First it wasn't able to meet demand, and then after beefing up its production capacity, its expected demand wasn't there. Part of the problem is Provenge's daunting price tag, costing $93,000 total for a one-month treatment. Meanwhile, new competitors are around the corner, such as Medivation
These stocks are far from doomed. Like any biotech enterprise, their fortunes are tied to the drugs that they successfully bring to market and how well they're sold and received. If you're intrigued by the sector but are skittish about investing in any particular company, consider a biotech ETF, which offers instant diversification.
Longtime Fool contributor Selena Maranjian owns shares of Teva Pharmaceutical Industries, but she holds no other position in any company mentioned. Click here to see her holdings and a short bio. The Motley Fool owns shares of Exelixis, Dendreon, and Teva Pharmaceutical. Motley Fool newsletter services have recommended buying shares of Teva Pharmaceutical and Exelixis.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Predicting Dendreon's Next CEO's Future
Its time to play Fool in the blank
Tuesday’s Top Biotech Stories: Achillion, Receptos, and Dendreon
Achillion, Receptos, and Dendreon could all make waves in biotech headlines this Tuesday morning.
Why Wall Street Hates Dendreon Corp.
Stocks with heavy short interest might signal that something is terribly wrong with a company. Dendreon Corp. sports one of the highest short interests among health-care stocks. Why are short-sellers so bearish on this small-cap biotech?